Myomo CMO granted 55,149 RSUs, 22,457 shares withheld

MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, reported equity compensation activity involving common stock.

Rhea-AI Filing Summary

MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, reported equity compensation activity involving common stock. On August 7, 2026, he received a grant of 55,149 fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. On the same date, 22,457 shares were disposed of and withheld solely to pay income and other taxes associated with the vesting of these RSUs.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kovelman Harry

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	55,149	$0.00	$0.00
Tax Withholding	Common Stock F2	22,457	$1.42	$32K

Holdings After Transaction: Common Stock — 123,233 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of fully vested Restricted Stock Units ("RSU's") as payment for incentive compensation for the Reporting Party earned for the fiscal year ended December 31, 2025.
2. F2. Represents shares withheld solely to pay income and other taxes associated with the aforementioned vesting of RSU's granted on August 7, 2026.

Key Figures

RSUs granted: 55,149 shares Shares withheld for taxes: 22,457 shares Withholding reference price: $1.42 per share +1 more

4 metrics

RSUs granted 55,149 shares Fully vested RSUs granted as incentive compensation for fiscal year ended December 31, 2025

Shares withheld for taxes 22,457 shares Shares withheld solely to pay income and other taxes on RSU vesting

Withholding reference price $1.42 per share Price associated with 22,457 shares withheld under code F

10b5-1 plan status Box unchecked Affirmation checkbox for Rule 10b5-1 trading arrangement is false

Key Terms

Restricted Stock Units, incentive compensation, withheld solely to pay income and other taxes, Reporting Party

4 terms

Restricted Stock Units financial

"Represents a grant of fully vested Restricted Stock Units ("RSU's") as payment"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

incentive compensation financial

"as payment for incentive compensation for the Reporting Party earned for the fiscal year"

Incentive compensation is pay tied to specific goals—such as bonuses, stock options, or commission—that rewards employees or executives when the company meets financial, operational, or strategic targets. For investors, it matters because it influences company costs, can encourage behavior that boosts long-term value (or short-term results), and may dilute existing shares if paid in stock; think of it as a performance-based reward system that aligns pay with outcomes.

withheld solely to pay income and other taxes financial

"Represents shares withheld solely to pay income and other taxes associated"

Reporting Party financial

"as payment for incentive compensation for the Reporting Party earned"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity compensation did MYO Chief Medical Officer Harry Kovelman receive?

Harry Kovelman received a grant of 55,149 fully vested RSUs of MYOMO, INC. common stock on August 7, 2026 as payment for incentive compensation earned for the fiscal year ended December 31, 2025.

How many MYO shares were withheld for taxes in this Form 4?

The filing reports that 22,457 shares of MYOMO, INC. common stock were withheld solely to pay income and other taxes associated with the vesting of the reported RSUs on August 7, 2026.

Was the MYO Form 4 transaction by Harry Kovelman a market sale?

No. The Form 4 states that 22,457 shares were disposed of under code F, representing shares withheld solely to pay income and other taxes tied to RSU vesting, not an open-market sale.

What period of performance did the MYO RSU grant compensate?

The RSU grant to Harry Kovelman compensated incentive awards earned for the fiscal year ended December 31, 2025. The grant of 55,149 fully vested RSUs was reported with a transaction date of August 7, 2026.

Is Harry Kovelman considered an officer of MYO in this filing?

Yes. The reporting person is identified as Harry Kovelman, serving as Chief Medical Officer of MYOMO, INC., making him an officer whose equity transactions must be reported on Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 08:08 AM Accepted by SEC EDGAR 08/11/2026 - 08:07 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovelman Harry

(Last) (First) (Middle)

C/O MYOMO, INC.

45 BLUE SKY DR., SUITE 101

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		A		55,149(1)	A	$0	145,690	D
Common Stock	08/07/2026		F		22,457(2)	D	$1.42	123,233	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested Restricted Stock Units ("RSU's") as payment for incentive compensation for the Reporting Party earned for the fiscal year ended December 31, 2025.

2. Represents shares withheld solely to pay income and other taxes associated with the aforementioned vesting of RSU's granted on August 7, 2026.

	/s/ David A. Henry, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)